TY - JOUR T1 - Higher left ventricular mass–wall stress–heart rate product and outcome in aortic valve stenosis JF - Heart JO - Heart DO - 10.1136/heartjnl-2018-314462 SP - heartjnl-2018-314462 AU - Eva Gerdts AU - Sahrai Saeed AU - Helga Midtbø AU - Anne Rossebø AU - John Boyd Chambers AU - Eigir Einarsen AU - Edda Bahlmann AU - Richard Devereux Y1 - 2019/06/01 UR - http://heart.bmj.com/content/early/2019/06/01/heartjnl-2018-314462.abstract N2 - Objective Whether increased myocardial oxygen demand could help explain the association of left ventricular (LV) hypertrophy with higher adverse event rate in patients with aortic valve stenosis (AS) is unknown.Methods Data from 1522 patients with asymptomatic mostly moderate AS participating in the Simvastatin-Ezetimibe in AS study followed for a median of 4.3 years was used. High LV mass–wall stress–heart rate product was identified as >upper 95% CI limit in normal subjects. The association of higher LV mass–wall stress–heart rate product with major cardiovascular (CV) events, combined CV death and hospitalised heart failure and all-cause mortality was tested in Cox regression analyses, and reported as HR and 95% CI.Results High LV mass–wall stress–heart rate product was found in 19% at baseline, and associated with male sex, higher body mass index, hypertension, LV hypertrophy, more severe AS and lower LV ejection fraction (all p<0.01). Adjusting for these confounders in time-varying Cox regression analysis, 1 SD higher LV mass–wall stress–heart rate product was associated with higher HR of major CV events (HR 1.16(95% CI 1.06 to 1.29)), combined CV death and hospitalised heart failure (HR 1.29(95% CI 1.09 to 1.54)) and all-cause mortality (HR 1.34(95% CI 1.13 to 1.58), all p<0.01).Conclusion In patients with initially mild–moderate AS, higher LV mass–wall stress–heart rate product was associated with higher mortality and heart failure hospitalisation. Our results suggest that higher myocardial oxygen demand is contributing to the higher adverse event rate reported in AS patients with LV hypertrophy.Trial registration number NCT000092677;Post-results. ER -